MC
DMRA

Maverick Capital’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Maverick Capital’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,252
Closed -$1.8M – 702
2021
Q2 		$1.8M Sell
14,252
-5,055
-26% -$689K 0.02% 181
2021
Q1 		$2.9M Sell
19,307
-311
-2% -$84.6K 0.03% 115
2020
Q4 		$5.85M Buy
+19,618
New +$7.3M 0.09% 57

Other funds holding DMRA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Maverick Capital's DMRA Position: Q3 2021 in Review

Maverick Capital sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q3 2021, closing a stake of 14,252 shares — an estimated $1.8M sold.

Maverick Capital first reported a position in DMRA in Q4 2020 and held it in 3 quarters. The position peaked at $5.85M in Q4 2020. 25 funds tracked by Wall St. Rank hold DMRA as of Q3 2021.

  • Maverick Capital reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q3 2021 after selling out during the quarter.
  • Maverick Capital sold 14,252 Damora Therapeutics, Inc. Ordinary Shares shares in Q3 2021, an estimated $1.8M.
  • Maverick Capital first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2020 and held it in 3 quarters.
  • Maverick Capital's Damora Therapeutics, Inc. Ordinary Shares position peaked at $5.85M in Q4 2020.
  • 25 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q3 2021.

Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.